Jump to navigation Jump to search

WikiDoc Resources for CHOP


Most recent articles on CHOP

Most cited articles on CHOP

Review articles on CHOP

Articles on CHOP in N Eng J Med, Lancet, BMJ


Powerpoint slides on CHOP

Images of CHOP

Photos of CHOP

Podcasts & MP3s on CHOP

Videos on CHOP

Evidence Based Medicine

Cochrane Collaboration on CHOP

Bandolier on CHOP


Clinical Trials

Ongoing Trials on CHOP at Clinical

Trial results on CHOP

Clinical Trials on CHOP at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on CHOP

NICE Guidance on CHOP





Books on CHOP


CHOP in the news

Be alerted to news on CHOP

News trends on CHOP


Blogs on CHOP


Definitions of CHOP

Patient Resources / Community

Patient resources on CHOP

Discussion groups on CHOP

Patient Handouts on CHOP

Directions to Hospitals Treating CHOP

Risk calculators and risk factors for CHOP

Healthcare Provider Resources

Symptoms of CHOP

Causes & Risk Factors for CHOP

Diagnostic studies for CHOP

Treatment of CHOP

Continuing Medical Education (CME)

CME Programs on CHOP


CHOP en Espanol

CHOP en Francais


CHOP in the Marketplace

Patents on CHOP

Experimental / Informatics

List of terms related to CHOP

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP stands for Cytoxan, Hydroxydaunorubicin (Adriamycin), Oncovin (Vincristine), Prednisone/Prednisolone.

Uses and indications

CHOP consists of:

This regimen can also be combined with the monoclonal antibody rituximab if the lymphoma is of B cell origin (R-CHOP or CHOP-R). Typically, courses are administered at an interval of three weeks. A staging CT scan is generally performed after three cycles to assess whether the disease is responding to treatment.

In patients with a history of cardiovascular disease, the doxorubicin (which is cardiotoxic) is often deemed to be too great a risk and is omitted from the regimen. The combination is then referred to as COP or CVP.

Side-effects and complications

The combination is generally well tolerated. Chemotherapy-induced nausea and vomiting may require antiemetics (such as ondansetron), and hemorrhagic cystitis is prevented with administration of mesna. Alopecia (hair loss) is common.

Neutropenia generally develops in the second week. During this period, many clinicians recommend prophylactic use of ciprofloxacin[2]. If a fever develops in the neutropenic period, urgent medical assessment is required for neutropenic sepsis, as infections in patients with low neutrophil counts may progress rapidly.

Allopurinol is typically co-administered prophylactically to prevent tumor lysis syndrome, the result of rapid death of tumor cells.


A pivotal study published in 1993 compared CHOP to several other chemotherapy regimens (e.g. m-BACOD, ProMACE-CytaBOM, MACOP-B).[3] CHOP emerged as the regimen with the least toxicity but similar efficacy.

See also


  1. ^ Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A (2005). "Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas". N Engl J Med. 353 (10): 988–98. PMID 16148284.
  2. ^ Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993). "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma". N Engl J Med. 328 (14): 1002–6. PMID 7680764.


Template:WikiDoc Sources